SCHEMBL1930382

SCHEMBL1930382

Cc1onc(-c2ccccc2)c1-c1nnc(-c2ccccc2OCc2ccccc2)o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.61
L3MBTL1 Q9Y468 2/20 0.59
PTGS1 P23219 2/20 0.47
PTGS2 P35354 2/20 0.47
NPSR1 Q6W5P4 3/20 0.46
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
USP2 O75604 2/20 0.46
TSHR P16473 2/20 0.46
HSD17B10 Q99714 2/20 0.46
XBP1 P17861 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
GABRA5 P31644 1/20 0.43
MAPT P10636 3/20 0.43
SGMS2 Q8NHU3 2/20 0.43
KMT2A Q03164 1/20 0.43
EGFR P00533 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1929424 0.89 L3MBTL1 (0.61) BRD4L3MBTL1PTGS1PTGS2NPSR1
SCHEMBL1930037 0.85 L3MBTL1 (0.65) L3MBTL1PTGS1PTGS2NPSR1KDM4E
SCHEMBL1930022 0.81 L3MBTL1 (0.70) L3MBTL1PTGS1PTGS2NPSR1KDM4E
SCHEMBL1930510 0.81 L3MBTL1 (0.64) L3MBTL1PTGS1PTGS2NPSR1KDM4E
SCHEMBL1930757 0.80 L3MBTL1 (0.71) L3MBTL1PTGS1PTGS2NPSR1KDM4E
SCHEMBL1930084 0.78 L3MBTL1 (0.67) BRD4L3MBTL1PTGS1PTGS2NPSR1
SCHEMBL1929139 0.77 L3MBTL1 (0.68) L3MBTL1PTGS1PTGS2NPSR1KDM4E
SCHEMBL1930432 0.77 L3MBTL1 (0.58) BRD4L3MBTL1PTGS1PTGS2NPSR1
SCHEMBL16493647 0.77 L3MBTL1 (0.53) BRD4L3MBTL1PTGS1PTGS2NPSR1
SCHEMBL1931172 0.76 L3MBTL1 (0.60) L3MBTL1PTGS1PTGS2NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968972-B1 ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-11-28 EP claimed
US-7541372-B2 Aryl-isoxazolo-4-yl-oxadiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-06-02 US claimed
US-20070161686-A1 Aryl-isoxazolo-4-yl-oxadiazole derivatives HOFFMANN-LA ROCHE INC. 2007-07-12 US claimed
EP-1968972-B1 ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-11-28 EP disclosed
US-7956074-B2 Aryl-isoxazolo-4-yl-oxadiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2011-06-07 US disclosed
US-20090197875-A1 ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES BUETTELMANN BERND 2009-08-06 US disclosed
US-7541372-B2 Aryl-isoxazolo-4-yl-oxadiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-06-02 US disclosed
US-20070161686-A1 Aryl-isoxazolo-4-yl-oxadiazole derivatives HOFFMANN-LA ROCHE INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197875-A1 ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES GABRA5, GABRA4, GABRA3 BRD4 1112/4885L3MBTL1 3503/4885PTGS1 3103/4885
US-20070161686-A1 Aryl-isoxazolo-4-yl-oxadiazole derivatives GABRA5, GABRA4, GABRA3 BRD4 1112/4885L3MBTL1 3503/4885PTGS1 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.